🔥🐔 BizChicken 🐔🔥
Companies Similar to Lexicon Pharmaceuticals, Inc.
Sign Up Today!
Sign up for BizChicken and discover more about the corporations around you.
Fulcrum Therapeutics, Inc.
losmapimod and FTX-6058
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing products to improve the lives of patients with genetically defined diseases in areas of high unmet medical need in the United States.
Symbol: FULC
Recent Price: $4.68
Industry: Biotechnology
CEO: Mr. Alexander C. Sapir
Sector: Healthcare
Employees: 76
Address: 26 Landsdowne Street, Cambridge, MA 02139
Phone: 617 651 8851
Last updated: 2024-12-31
Lixte Biotechnology Holdings, Inc.
LB-100 series and LB-200 series
Lixte Biotechnology Holdings, Inc. is a drug discovery company leveraging biomarker technology to develop enzyme-targeting drugs for cancer, vascular, metabolic, hereditary, and neurodegenerative diseases.
Symbol: LIXT
Recent Price: $2.00
Industry: Biotechnology
CEO: Mr. Bastiaan van der Baan M.Sc.
Sector: Healthcare
Employees: 3
Address: 680 East Colorado Boulevard, Pasadena, CA 91101
Phone: 631 830 7092
Last updated: 2024-12-31
Lexicon Pharmaceuticals, Inc.
Sotagliflozin, LX9211
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of pharmaceutical products, with drugs like Sotagliflozin and LX9211 under development for heart failure, type 1 diabetes, and neuropathic pain.
About | Foundation | Leadership | Contact | Careers | Careers | About | About | About | Careers | About
Symbol: LXRX
Recent Price: $0.72
Industry: Biotechnology
CEO: Dr. Michael Exton Ph.D.
Sector: Healthcare
Employees: 285
Address: 2445 Technology Forest Boulevard, The Woodlands, TX 77381
Phone: 281 863 3000
Leadership
- Brian Corrigan, Senior Vice President, Regulatory and Quality Assurance
- Brian Crum, Senior Vice President and General Counsel
- Lisa DeFrancesco, Vice President, Investor Relations and Corporate Communications
- Mike Exton, Ph.D., Chief Executive Officer and Director
- Tom Garner, Senior Vice President and Chief Commercial Officer
- Craig Granowitz, MD, PhD, Senior Vice President and Chief Medical Officer
- Alan Main, PhD, Executive Vice President, Innovation and Chemical Sciences
- Wendy McDermott, Senior Vice President, Human Resources
- Kristen Alexander, Vice President, Finance and Accounting
- Phillip Banks, MS, FRS, Vice President, Biostatistics and Data Management
- Kyle Burt, Vice President, Information Operations
- Amy Carroll, Ph.D., Vice President, Medical Affairs
- Melinda Francini, Vice President, Value and Access
- Desiree Gendron, Vice President, Sales and Training
- Suma Gopinathan, Ph.D., Vice President, Clinical Development
- Rachel Martens, Vice President, Partnerships and Corporate Strategy
- Nicole Moore, Vice President, Legal
- Tracy Newbold, Vice President, Clinical Operations
- Godfried Owusu-Ababio, Vice President, Technical Operations
- Rob Scala, Vice President, Business Planning and Commercial Operations
- Carrie Siragusa, Vice President, Marketing
- Dixon Terry, Vice President, Compliance
- Raymond Debbane, Chairman
- Philippe J. Amouyal,
- Samuel L. Barker, PhD,
- Robert J. Lefkowitz, MD,
- Christopher J. Sobecki,
- Diane E. Sullivan,
- Judith L. Swain, MD,
Last updated: 2024-12-31
NRx Pharmaceuticals, Inc.
ZYESAMI, NRX-100, NRX-101
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases.
Symbol: NRXP
Recent Price: $1.53
Industry: Biotechnology
CEO: Dr. Jonathan C. Javitt M.D., M.P.H.
Sector: Healthcare
Employees: 2
Address: 1201 Orange Street, Wilmington, DE 19801
Phone: 484 254 6134
Last updated: 2024-12-31
Syndax Pharmaceuticals, Inc.
SNDX-5613, SNDX-6352 (axatilimab), Entinostat
Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for cancer treatment, including innovative candidates like SNDX-5613 and SNDX-6352. It collaborates with notable institutions like the National Cancer Institute and has a license agreement with Kyowa Hakko Kirin Co., Ltd.
Symbol: SNDX
Recent Price: $12.52
Industry: Biotechnology
CEO: Mr. Michael A. Metzger M.B.A.
Sector: Healthcare
Employees: 184
Address: 35 Gatehouse Drive, Waltham, MA 02451
Phone: 781 419 1400
Last updated: 2024-12-31
Tenax Therapeutics, Inc.
TNX-103, TNX-102 (levosimendan), TNX-201 (imatinib)
Tenax Therapeutics, Inc. is a specialty pharmaceutical company that focuses on identifying, developing, and commercializing products for cardiovascular and pulmonary diseases. The company is involved in developing medications such as TNX-103 and TNX-102 (levosimendan) for pulmonary hypertension and heart failure, and TNX-201 (imatinib) for pulmonary arterial hypertension.
Symbol: TENX
Recent Price: $6.55
Industry: Biotechnology
CEO: Mr. Christopher T. Giordano
Sector: Healthcare
Employees: 5
Address: ONE Copley Parkway, Morrisville, NC 27560
Phone: 919 855 2100
Last updated: 2024-12-31
Tonix Pharmaceuticals Holding Corp.
TNX-1500, TNX-2900, TNX-801, TNX-1840, TNX-1850, TNX-3500
Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company that focuses on developing therapies for immunology, rare diseases, infectious diseases, and central nervous system disorders. Key products include TNX-1500 for organ transplant and autoimmune diseases, TNX-2900 for Prader-Willi syndrome, and TNX-801 for smallpox prevention.
Symbol: TNXP
Recent Price: $0.36
Industry: Biotechnology
CEO: Dr. Seth Lederman M.D.
Sector: Healthcare
Employees: 103
Address: 26 Main Street, Chatham, NJ 07928
Phone: 862 799 8599
Last updated: 2024-12-31
Amylyx Pharmaceuticals, Inc.
AMX0035
Amylyx Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Their leading product, AMX0035, is aimed at ALS treatment.
About | Leadership | Directors | Contact | Careers | About | About | About | About | About | About | About | About | News | About
Symbol: AMLX
Recent Price: $3.84
Industry: Biotechnology
CEO: Mr. Joshua B. Cohen
Sector: Healthcare
Employees: 384
Address: 43 Thorndike Street, Cambridge, MA 02141
Phone: 617 682 0917
Leadership
- Linda A. Arsenault, Chief Human Resources Officer
- Camille L. Bedrosian, MD, Chief Medical Officer
- Josh Cohen, Co-CEO & Co-Founder
- James M. Frates, Chief Financial Officer
- Tom Holmes, Chief Technical Operations Officer
- Justin Klee, Co-CEO & Co-Founder
- Gina M. Mazzariello, Chief Legal Officer & General Counsel
- Rudolph Tanzi, PhD, Founding Chair of the Amylyx SAB
- Wally Gilbert, Special Advisor
- Kari Firestone, Director
- Paul Fonteyne, Director
- George Milne, Chairman
- Daphne Quimi, Director
- Bernhardt G. Zeiher, MD, FACP, FCCP, Director
Last updated: 2024-12-31
Eloxx Pharmaceuticals, Inc.
ELX-02
Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing ribosome modulation therapies for rare and ultra-rare premature stop codon diseases. The company's lead investigational drug, ELX-02, is in Phase 2 clinical trials for cystic fibrosis and nephropathic cystinosis.
Symbol: ELOX
Recent Price: $0.00
Industry: Biotechnology
CEO: Mr. Sumit Aggarwal M.B.A.
Sector: Healthcare
Employees: 18
Address: 480 Arsenal Way, Watertown, MA 02472
Phone: 781 577 5300
Last updated: 2024-12-31
Esperion Therapeutics, Inc.
NEXLETOL and NEXLIZET
Esperion Therapeutics, Inc. is a pharmaceutical company focused on developing and commercializing medicines for treating elevated low density lipoprotein cholesterol. Its main products are NEXLETOL and NEXLIZET, aimed at treating conditions like atherosclerotic cardiovascular disease.
About | Leadership | Directors | About | ESG | About | Contact | Careers | About | About | About
Symbol: ESPR
Recent Price: $2.28
Industry: Drug Manufacturers - Specialty & Generic
CEO: Mr. Sheldon L. Koenig
Sector: Healthcare
Employees: 240
Address: 3891 Ranchero Drive, Ann Arbor, MI 48108
Phone: 734 887 3903
Leadership
- Sheldon Koenig, Chief Executive Officer
- Glenn Brame, Chief Technical Operations Officer
- Ben Halladay, Chief Financial Officer, MBA
- Benjamin O. Looker, General Counsel
- Betty Jean (BJ) Swartz, Chief Business Officer
- Eric Warren, R.Ph., Chief Commercial Officer
- J. Martin Carroll, Chairman of the Board
- Seth H.Z. Fischer, Member of the Compliance Committee Chair of the Compensation Committee
- Alan Fuhrman, Chief Financial Officer
- Antonio Gotto, Jr., MD, DPhil, Member of the Nominating and Governance Committee
- Stephen Rocamboli, Chief Executive Officer of Innovatrx, Inc.
- Jay Shepard, Venture Partner with Catalys Pacific
- Nicole Vitullo, Lead Independent Director
- Tracy Woody, Member of the Nominating and Governance Committee Chair of the Compliance Committee
Last updated: 2024-11-08
Ligand Pharmaceuticals Incorporated
Kyprolis, Evomela, Veklury, Teriparatide, Vaxneuvance, Pneumosil, Rylaze, Nexterone, Zulresso, Noxafil-IV
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company focused on developing or acquiring technologies to aid pharmaceutical companies in discovering and developing medicines. The company's commercial programs include treatments for multiple myeloma, COVID-19, osteoporosis, invasive diseases, childhood pneumonia, and acute lymphoblastic leukemia.
Symbol: LGND
Recent Price: $105.76
Industry: Biotechnology
CEO: Mr. Todd C. Davis Ph.D.
Sector: Healthcare
Employees: 58
Address: 5980 Horton Street, EmeryVille, CA 94608
Phone: 858 550 7500
Last updated: 2024-12-31
Lantern Pharma Inc.
LP-100
Lantern Pharma Inc. is a clinical stage biotechnology company focused on using artificial intelligence, machine learning, and genomic data to streamline drug development, with key drug candidates including LP-100, LP-300, and LP-184 for various cancer treatments.
About | About | About | About | Contact | About | Careers | Careers | About | About | About | About | About | About | About | About | About
Symbol: LTRN
Recent Price: $3.27
Industry: Biotechnology
CEO: Mr. Panna Sharma PH.D.
Sector: Healthcare
Employees: 21
Address: 1920 McKinney Avenue, Dallas, TX 75201
Phone: 972 277 1136
Last updated: 2024-12-31
Lumos Pharma, Inc.
LUM-201
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for rare diseases, with its lead candidate LUM-201 in a Phase 2 trial for pediatric growth hormone deficiency.
Symbol: LUMO
Recent Price: $4.34
Industry: Biotechnology
CEO: Mr. Richard J. Hawkins
Sector: Healthcare
Employees: 33
Address: 4200 Marathon Boulevard, Austin, TX 78756
Phone: 512 215 2630
Last updated: 2024-12-31
Lexeo Therapeutics, Inc. Common Stock
LX2006, LX2020, LX2021, LX2022, LX1001, LX1020, LX1021, LX1004
Lexeo Therapeutics is a clinical-stage genetic medicine company developing innovative gene therapy candidates targeting hereditary and acquired diseases, including cardiomyopathies and neurological conditions.
Symbol: LXEO
Recent Price: $6.54
Industry: Biotechnology
CEO: Mr. R. Nolan Townsend
Sector: Healthcare
Employees: 69
Address: 345 Park Avenue South, New York, null 10010
Phone: 212-547-9879
Last updated: 2024-12-31
Nurix Therapeutics, Inc.
NX-2127, NX-5948, NX-1607, NX-0255
Nurix Therapeutics, Inc. is a biopharmaceutical company that focuses on developing small molecule therapies for cancer and immune disorders, with products targeting BTK and CBL-B proteins. The company collaborates with Gilead Sciences and Sanofi.
Symbol: NRIX
Recent Price: $18.64
Industry: Biotechnology
CEO: Dr. Arthur T. Sands M.D., Ph.D.
Sector: Healthcare
Employees: 284
Address: 1700 Owens Street, San Francisco, CA 94158
Phone: 415 660 5320
Last updated: 2024-12-31
Scilex Holding Company
ZTlido 1.8%
Scilex Holding Company is a biopharmaceutical company focused on developing and commercializing non-opioid management products for the treatment of acute and chronic pain, including its commercial product ZTlido 1.8% and several products in clinical trial stages.
About | About | About | News | News | Contact | Contact | Contact | About | About | About | About
Symbol: SCLX
Recent Price: $0.42
Industry: Drug Manufacturers - General
CEO: Mr. Jaisim Shah
Sector: Healthcare
Employees: 113
Address: 960 San Antonio Road, Palo Alto, CA 94303
Phone: 650-516-4310
Last updated: 2024-12-31
scPharmaceuticals Inc.
FUROSCIX
sc Pharmaceuticals Inc. is a pharmaceutical company focused on developing and commercializing pharmaceutical products, with a lead product candidate, FUROSCIX, aimed at treating congestion in heart failure patients using an on-body infusor.
About | Leadership | Contact | Contact | Careers | About | About | About | About | Careers | Careers | Careers | Careers | About | About | About
Symbol: SCPH
Recent Price: $3.50
Industry: Biotechnology
CEO: Mr. John H. Tucker
Sector: Healthcare
Employees: 135
Address: 2400 District Avenue, Burlington, MA 01803
Phone: 617 517 0730
Leadership
- John H. Tucker, President and Chief Executive Officer
- Rachael Nokes, Chief Financial Officer
- Mike Hassman, Senior Vice President, Technical Operations
- John Mohr, Pharm.D., FIDP, Senior Vice President, Clinical Development and Medical Affairs
- William T. Abraham, MD,
- Mette Kirstine Agger, Co-Founder & CEO, 7TM Pharma A/S
- Minnie V. Baylor-Henry, President, B-Henry & Associates
- Sara Bonstein, CFO, Insmed Incorporated
- Frederick Hudson, Former Partner in Charge of KPMG’s Largest Healthcare Industry Audit Practice Located in the Mid-Atlantic Region
- Jack A. Khattar, Founder, President & Chief Executive Officer, Supernus Pharmaceuticals
- Leonard D. Schaeffer, Founding Chairman & CEO, Wellpoint
- Klaus Veitinger, MD, PhD, Venture Partner, Orbimed
- Dan Bensimhon, MD, Medical Director Advanced Heart Failure & Mechanical Circulatory Support Program, Cone Health, Greensboro, NC
- G. Michael Felker, MD, Chief, Heart Failure Service, Division of Cardiology, Duke University School of Medicine
- Marv Konstam, MD, Professor of Medicine, Tufts University School of Medicine, Chief Physician Executive of the Cardiovascular Center at Tufts Medical Center
- W. Frank Peacock, MD, FACEP, FACC, FESC, Professor, Vice Chair of Research, Department of Emergency Medicine, Baylor College of Medicine, Ben Taub General Hospital
- Stuart Russell, MD, Regional Director of Heart Failure Program, Duke University School of Medicine
- James E. Udelson, MD, Chief, Division of Cardiology, Tufts Medical Center, Professor of Medicine and Radiology Tufts University School of Medicine
- William Weintraub, MD, Director of Outcomes Research, MedStar Heart and Vascular Institute
Last updated: 2024-12-31
Soligenix, Inc.
SGX301 (Hy Bryte), SGX942, SGX203, SGX302
Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases, operating in the Specialized Bio Therapeutics and Public Health Solutions segments.
About | Directors | About | About | About | About | About | About | Contact | About | About | About | About | About | Careers | Careers | About | About | About | About | About | About | About
Symbol: SNGX
Recent Price: $2.91
Industry: Biotechnology
CEO: Dr. Christopher J. Schaber Ph.D.
Sector: Healthcare
Employees: 13
Address: 29 Emmons Drive, Princeton, NJ 08540
Phone: 609 538 8200
Leadership
- Christopher J. Schaber, PhD, Chairman, President and Chief Executive Officer
- Gregg A. Lapointe, CPA, MBA, Board Director
- Diane L. Parks, MBA, Board Director
- Robert J. Rubin, MD, Board Director
- Jerome Zeldis, MD, PhD, Board Director
Last updated: 2024-12-31
Synlogic, Inc.
Synthetic Biotic Medicines
Synlogic, Inc. is a clinical-stage biopharmaceutical company focused on the development of synthetic biotic medicines to treat metabolic and immunological diseases. The company's pipeline includes drug candidates for conditions such as phenylketonuria, homocystinuria, enteric hyperoxaluria, and solid tumors and lymphoma.
Symbol: SYBX
Recent Price: $1.40
Industry: Biotechnology
CEO: Mr. Antoine Awad
Sector: Healthcare
Employees: 6
Address: 301 Binney Street, Cambridge, MA 02142
Phone: 617 401 9975
Last updated: 2024-12-31
Seelos Therapeutics, Inc.
SLS-002, SLS-005, SLS-006, SLS-007, SLS-008, SLS-004, SLS-010
Seelos Therapeutics, Inc. is focused on developing and commercializing therapeutics for central nervous system, respiratory, and other disorders, with lead programs targeting major depressive disorders, amyotrophic lateral sclerosis, Sanfilippo syndrome, and Parkinson's disease.
Symbol: SEEL
Recent Price: $0.37
Industry: Biotechnology
CEO: Dr. Raj Mehra J.D., Ph.D.
Sector: Healthcare
Employees: 8
Address: 300 Park Avenue, New York, NY 10022
Phone: 646 293 2100
Last updated: 2024-12-31